Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal down4.930 -0.060 (-1.202%)
Others

08/10/2018 14:27

CSPC Pharma granted exclusive right for Sinocelltech product

[ET Net News Agency, 8 October 2018] CSPC Pharmaceutical (01093) said it has entered
into an agreement with Sinocelltech in relation to the licensing and commercialization of
an antiCD20 monoclonal antibody for injection (SCT400) developed by Sinocelltech. The
product is currently undergoing phase III clinical trials in China for the indication of
non-Hodgkin's lymphoma and biologics license application is expected to be filed in the
first quarter of 2019.
The company agrees to pay to Sinocelltech upfront and development milestone payments of
up to a maximum amount of RMB650 million. (SC)

Back to Others

Remark: Real time quote last updated: 23/09/2024 16:10
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.